Literature DB >> 26069209

Reply to Fišer et al.: Myeloid reprogramming of Ph+ B-ALL: A potential therapeutic strategy.

Ravindra Majeti1, Christopher Dove2, James Scott McClellan2.   

Abstract

Mesh：

Year:  2015        PMID： 26069209      PMCID： PMC4500202          DOI： 10.1073/pnas.1509027112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  4 in total

1.  Reprogramming of B cell acute lymphoblastic leukemia cells: Do we need to shoot a moving target?

Authors:  Karel Fišer; Lucie Slámová; Jean-Pierre Bourquin; Jan Trka; Jan Starý; Ondřej Hrušák; Ester Mejstříková
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-11       Impact factor: 11.205

2.  Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages.

Authors:  James Scott McClellan; Christopher Dove; Andrew J Gentles; Christine E Ryan; Ravindra Majeti
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-16       Impact factor: 11.205

3.  CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage.

Authors:  L Slamova; J Starkova; E Fronkova; M Zaliova; L Reznickova; F W van Delft; E Vodickova; J Volejnikova; Z Zemanova; K Polgarova; G Cario; M Figueroa; T Kalina; K Fiser; J P Bourquin; B Bornhauser; M Dworzak; J Zuna; J Trka; J Stary; O Hrusak; E Mejstrikova
Journal:  Leukemia       Date:  2013-11-25       Impact factor: 11.528

4.  Lineage switch at relapse of childhood acute leukemia: a report of four cases.

Authors:  Meerim Park; Kyung Nam Koh; Bo Eun Kim; Ho Joon Im; Seongsoo Jang; Chan-Jeoung Park; Hyun-Sook Chi; Jong Jin Seo
Journal:  J Korean Med Sci       Date:  2011-05-18       Impact factor: 2.153
  4 in total
  1 in total

Review 1.  Cancer cell reprogramming: a promising therapy converting malignancy to benignity.

Authors:  Lanqi Gong; Qian Yan; Yu Zhang; Xiaona Fang; Beilei Liu; Xinyuan Guan
Journal:  Cancer Commun (Lond)       Date:  2019-08-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.